Summit Therapeutics Inc. (SMMT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
33/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSMMT / S&P -23.15% / 15.20% |
LoseSMMT / S&P SMMT unavailable / 15.00% |
LoseSMMT / S&P 8.82% / 50.40% |
| 2026-Q12/3 |
WinSMMT / S&P 8.40% / -4.33% |
LoseSMMT / S&P SMMT unavailable / 11.30% |
WinSMMT / S&P 354.29% / 27.70% |
| 2025-Q41/3 |
LoseSMMT / S&P -15.34% / 2.65% |
LoseSMMT / S&P SMMT unavailable / 9.00% |
WinSMMT / S&P 350.00% / 13.40% |
| 2025-Q31/3 |
LoseSMMT / S&P -2.91% / 8.12% |
LoseSMMT / S&P SMMT unavailable / 4.61% |
WinSMMT / S&P 420.83% / 13.45% |
| 2025-Q21/3 |
LoseSMMT / S&P 10.32% / 10.94% |
LoseSMMT / S&P SMMT unavailable / 4.83% |
WinSMMT / S&P 436.84% / 10.63% |
| 2025-Q12/3 |
WinSMMT / S&P 8.10% / -4.27% |
LoseSMMT / S&P SMMT unavailable / 4.98% |
WinSMMT / S&P 191.67% / 10.57% |
| 2024-Q40/3 |
LoseSMMT / S&P -18.52% / 2.41% |
LoseSMMT / S&P SMMT unavailable / 5.25% |
LoseSMMT / S&P -78.52% / 6.15% |
| 2024-Q31/3 |
WinSMMT / S&P 180.77% / 5.89% |
LoseSMMT / S&P SMMT unavailable / 5.89% |
LoseSMMT / S&P -84.21% / 6.11% |
| 2024-Q21/3 |
WinSMMT / S&P 88.41% / 4.28% |
LoseSMMT / S&P SMMT unavailable / 5.38% |
LoseSMMT / S&P -88.05% / 5.12% |
| 2024-Q11/3 |
WinSMMT / S&P 58.62% / 10.56% |
LoseSMMT / S&P SMMT unavailable / 5.71% |
LoseSMMT / S&P -92.90% / 5.59% |
| 2023-Q42/3 |
WinSMMT / S&P 39.57% / 11.69% |
LoseSMMT / S&P -100.00% / 6.81% |
WinSMMT / S&P 263.41% / 7.78% |
| 2023-Q31/3 |
LoseSMMT / S&P -25.50% / -3.27% |
LoseSMMT / S&P -100.00% / 7.52% |
WinSMMT / S&P 310.81% / -5.03% |
| 2023-Q22/3 |
WinSMMT / S&P 43.43% / 8.74% |
LoseSMMT / S&P -89.24% / 9.50% |
WinSMMT / S&P 238.30% / -8.57% |
| 2023-Q11/3 |
LoseSMMT / S&P -58.82% / 7.50% |
LoseSMMT / S&P -75.63% / 10.77% |
WinSMMT / S&P 172.58% / -15.69% |
| 2022-Q41/3 |
WinSMMT / S&P 257.14% / 7.56% |
LoseSMMT / S&P -61.03% / 11.88% |
LoseSMMT / S&P -39.71% / -17.99% |
| 2022-Q31/3 |
WinSMMT / S&P 19.00% / -4.88% |
LoseSMMT / S&P -45.15% / 13.47% |
LoseSMMT / S&P -56.98% / -1.41% |
| 2022-Q21/3 |
LoseSMMT / S&P -59.18% / -16.10% |
WinSMMT / S&P 232.52% / 13.71% |
LoseSMMT / S&P -48.91% / 11.04% |
| 2022-Q11/3 |
LoseSMMT / S&P -8.92% / -4.60% |
WinSMMT / S&P 156.46% / 15.97% |
LoseSMMT / S&P -29.55% / 42.23% |
| 2021-Q41/3 |
LoseSMMT / S&P -46.31% / 11.03% |
WinSMMT / S&P 110.35% / 15.00% |
LoseSMMT / S&P -10.53% / 96.40% |
| 2021-Q30/3 |
LoseSMMT / S&P -32.84% / 0.58% |
LoseSMMT / S&P SMMT unavailable / 10.77% |
LoseSMMT / S&P SMMT unavailable / 69.42% |
| 2021-Q21/3 |
WinSMMT / S&P 27.09% / 8.55% |
LoseSMMT / S&P SMMT unavailable / 6.58% |
LoseSMMT / S&P SMMT unavailable / 51.81% |
| 2021-Q11/3 |
WinSMMT / S&P 24.89% / 6.17% |
LoseSMMT / S&P SMMT unavailable / -1.06% |
LoseSMMT / S&P SMMT unavailable / 7.39% |
| 2020-Q41/3 |
WinSMMT / S&P 36.63% / 12.15% |
LoseSMMT / S&P SMMT unavailable / -3.72% |
LoseSMMT / S&P SMMT unavailable / -33.42% |
| 2020-Q31/3 |
WinSMMT / S&P 15.82% / 8.93% |
LoseSMMT / S&P SMMT unavailable / -2.04% |
LoseSMMT / S&P SMMT unavailable / -27.10% |
| 2020-Q21/3 |
WinSMMT / S&P 25.32% / 20.54% |
LoseSMMT / S&P SMMT unavailable / -0.46% |
LoseSMMT / S&P SMMT unavailable / -27.11% |
| 2020-Q11/3 |
WinSMMT / S&P 48.13% / -19.60% |
LoseSMMT / S&P SMMT unavailable / 3.47% |
LoseSMMT / S&P SMMT unavailable / -14.75% |
| 2019-Q40/3 |
LoseSMMT / S&P -10.61% / 9.07% |
LoseSMMT / S&P SMMT unavailable / 5.36% |
LoseSMMT / S&P SMMT unavailable / 2.99% |
| 2019-Q31/3 |
WinSMMT / S&P 41.50% / 1.70% |
LoseSMMT / S&P SMMT unavailable / 5.02% |
LoseSMMT / S&P SMMT unavailable / 0.21% |
| 2019-Q20/3 |
LoseSMMT / S&P -30.87% / 4.30% |
LoseSMMT / S&P SMMT unavailable / 6.64% |
LoseSMMT / S&P SMMT unavailable / 8.65% |
| 2019-Q11/3 |
WinSMMT / S&P 59.13% / 13.65% |
LoseSMMT / S&P SMMT unavailable / 8.12% |
LoseSMMT / S&P SMMT unavailable / 14.29% |
| 2018-Q40/3 |
LoseSMMT / S&P -48.20% / -13.52% |
LoseSMMT / S&P SMMT unavailable / 9.05% |
LoseSMMT / S&P SMMT unavailable / 18.23% |
| 2018-Q30/3 |
LoseSMMT / S&P -9.39% / 7.71% |
LoseSMMT / S&P SMMT unavailable / 10.21% |
LoseSMMT / S&P SMMT unavailable / 19.06% |
| 2018-Q20/3 |
LoseSMMT / S&P -81.01% / 3.43% |
LoseSMMT / S&P SMMT unavailable / 9.03% |
LoseSMMT / S&P SMMT unavailable / 14.46% |
| 2018-Q11/3 |
WinSMMT / S&P 16.43% / -0.76% |
LoseSMMT / S&P SMMT unavailable / 7.68% |
LoseSMMT / S&P SMMT unavailable / 12.46% |
| 2017-Q40/3 |
LoseSMMT / S&P -11.71% / 6.64% |
LoseSMMT / S&P SMMT unavailable / 7.03% |
LoseSMMT / S&P SMMT unavailable / 13.82% |
| 2017-Q31/3 |
WinSMMT / S&P 10.18% / 4.48% |
LoseSMMT / S&P SMMT unavailable / 5.68% |
LoseSMMT / S&P SMMT unavailable / 17.57% |
| 2017-Q20/3 |
LoseSMMT / S&P -14.20% / 3.09% |
LoseSMMT / S&P SMMT unavailable / 4.83% |
LoseSMMT / S&P SMMT unavailable / 17.74% |
| 2017-Q11/3 |
WinSMMT / S&P 55.08% / 6.07% |
LoseSMMT / S&P SMMT unavailable / 3.67% |
LoseSMMT / S&P SMMT unavailable / 13.32% |
| 2016-Q40/3 |
LoseSMMT / S&P -5.56% / 3.82% |
LoseSMMT / S&P SMMT unavailable / 2.09% |
LoseSMMT / S&P SMMT unavailable / 7.05% |
| 2016-Q31/3 |
WinSMMT / S&P 12.04% / 3.85% |
LoseSMMT / S&P SMMT unavailable / 0.20% |
LoseSMMT / S&P SMMT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SMMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -39.54% | 20.78% |
| Annualized return | -39.54% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SMMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 96.84% | 83.14% |
| Annualized return | 14.50% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SMMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 115.52% | 319.30% |
| Annualized return | 7.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |